Souhaitez-vous accéder aux communiqués récents ?

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially...

Dublin, April 30, 2026 (GLOBE NEWSWIRE) -- The "Deoxycholic Acid Obesity Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The deoxycholic acid obesity drugs market...

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight...

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...

Kailera Therapeutics, Inc. (Nasdaq: KLRA), an advanced clinical-stage biotechnology company, today announced the closing of its initial public offering.

Kailera Therapeutics, Inc. (Nasdaq: KLRA) today announced the pricing of its initial public offering.

Riyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) -- On the evening of April 15, HRH Prince Turki Alfaisal, Acting Chairman of the Board of Trustees of King Faisal Foundation, and King Faisal...

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting